Biogen’s chief executive George Scangos is to leave the company after six years at the helm, having transformed the company into a fast-growing mid-sized pharma company.
A court in Germany has suspended a trial discussing litigation brought against BioNTech and Pfizer by CureVac alleging patent infringement in connection with their mRNA-ba
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho